Role of the Immune System in Preventing Laryngeal Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Head & Neck Cancer. Basic parameters: 18 years — 99 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Italy
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Laryngeal Dysplasia and Progression to Carcinoma: Investigating Genetic and Immune Alterations Predictive of Malignant Transformation
Overview
Laryngeal dysplasia and progression to carcinoma: investigating genetic and immune alterations predictive of malignant transformation
Detailed description
Evaluate the immune population of TILs in LDy lesions with a high or low risk of malignant transformation. Analyze gene expression profiles in LDy lesions categorized by their risk of malignant progression.
Primary outcome measures
- differences in TILs counts [Time frame: 2 years]
Secondary outcome measures (1)
- Differences in TILs counts in LDy lesions [Time frame: 2 years]
Eligibility criteria
Inclusion criteria
- Histopathological diagnosis of laryngeal dysplasia.
- Age >18 years and informed consent.
Exclusion criteria
- Prior surgical, radiotherapeutic, or oncologic treatments for head and neck regions.
- Congenital or acquired immunodeficiency disorders.
- Synchronous malignancies.
- Immunosuppressive therapy.
- Age <18 years or absence of research consent.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Italy · 1 center
- European Institute of Oncology — Milan
Identifiers
NCT: NCT07508319 · UID 4973 · L2-401